The Company maintains a collaborative program with M. D. Anderson focused on development of this novel class of compounds possessing an important new mechanism of action that targets a variety of solid and hematologic tumors. In particular, this class of compounds promotes selective degradation of key proteins involved in cancer cell survival and proliferation. Data indicate that this degradation is specific for BCR-ABL, C-MYC and JAK-2, all key targets for many cancer research programs. Compounds from this class have shown excellent anti-cancer activity in in vitro assays and several animal models. The Company intends to identify the first clinical candidate for development, and file an IND within 2 years.
